@Article{info:doi/10.2196/26574,
author="Veldhuijzen, Evalien
and Walraven, Iris
and Belderbos, Jos{\'e}",
title="Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study",
journal="JMIR Cancer",
year="2021",
month="Sep",
day="14",
volume="7",
number="3",
pages="e26574",
keywords="PRO-CTCAE; lung cancer; side effects; patient-reported outcomes; PROM; symptomatic adverse events",
abstract="Background: The Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item library covers a wide range of symptoms relevant to oncology care. There is a need to select a subset of items relevant to specific patient populations to enable the implementation of PRO-CTCAE--based symptom monitoring in clinical practice. Objective: The aim of this study is to develop a PRO-CTCAE--based subset relevant to patients with lung cancer that can be used for monitoring during multidisciplinary clinical practice. Methods: The PRO-CTCAE--based subset for patients with lung cancer was generated using a mixed methods approach based on the European Organization for Research and Treatment of Cancer guidelines for developing questionnaires, comprising a literature review and semistructured interviews with both patients with lung cancer and health care practitioners (HCPs). Both patients and HCPs were queried on the relevance and impact of all PRO-CTCAE items. The results were summarized, and after a final round of expert review, a selection of clinically relevant items for patients with lung cancer was made. Results: A heterogeneous group of patients with lung cancer (n=25) from different treatment modalities and HCPs (n=22) participated in the study. A final list of eight relevant PRO-CTCAE items was created: decreased appetite, cough, shortness of breath, fatigue, constipation, nausea, sadness, and pain (general). Conclusions: On the basis of the literature and both professional and patient input, a subset of PRO-CTCAE items has been identified for use in patients with lung cancer in clinical practice. Future work is needed to confirm the validity and effectiveness of this PRO-CTCAE--based lung cancer subset internationally and in real-world clinical practice settings. ",
issn="2369-1999",
doi="10.2196/26574",
url="https://cancer.jmir.org/2021/3/e26574",
url="https://doi.org/10.2196/26574",
url="http://www.ncbi.nlm.nih.gov/pubmed/34519658"
}